RESUMEN
We have investigated the effect of partial hepatectomy (HEP) on tumor growth. MH-134 hepatoma cells, which were inoculated in syngeneic C3H/He mice from 3 to 10 days after HEP, grew with a linear increase in size until 7 days, began to regress, and disappeared 14 days after the inoculation. The survival rate was 100%, and the recurrence of tumor was not observed during the following 4 mo. On the other hand, the growth of another syngeneic tumor, X-5563, and of an allogeneic Ehrlich tumor was not affected by HEP. When MH-134 tumor cells were inoculated 7 days before or 15 days after HEP, tumor regression was not observed. The Winn assay showed the presence of tumor-neutralizing activity in spleen cells of MH-134 tumor-regressed mice. Cytotoxic activity against MH-134 tumor cells was also detected in the spleen cells. Analysis by using monoclonal antibodies showed that the effector cells were Thy-1+ and Lyt-2+ cells. Thus, HEP and the following liver cell regeneration may play a role in augmentation of specific immune response to the transplanted hepatoma cells.
Asunto(s)
Hepatectomía , Neoplasias Hepáticas Experimentales/inmunología , Animales , Citotoxicidad Inmunológica , Interleucina-2 , Células Asesinas Naturales/inmunología , Neoplasias Hepáticas Experimentales/mortalidad , Regeneración Hepática , Activación de Linfocitos , Ratones , Ratones Endogámicos C3H , Trasplante de Neoplasias , Pruebas de Neutralización , Bazo/inmunologíaRESUMEN
We evaluated the antitumor effect of an interleukin 2 (IL-2) slow delivery system, the IL-2 minipellet, using a murine hepatic metastasis model. The IL-2 minipellet consists of atelocollagen derived from natural bovine skin together with 1 x 10(6) units of recombinant IL-2. Administration of the IL-2 minipellet was performed into the spleens of BALB/c mice after translocation of the spleens to the s.c. position. Administration produced detectable serum IL-2 levels for 72 h. The IL-2 minipellet was evaluated for its efficacy against hepatic metastases from colon 26 adenocarcinoma in the BALB/c mice. Both the administration of the IL-2 minipellet alone and its combination with the injection of 5 x 10(7) lymphokine-activated killer cells resulted in significant reductions of the number of metastatic nodules. Moreover, increased survival of mice bearing colon 26 adenocarcinoma was noted in these two treatment groups. To investigate the mechanism of the IL-2 minipellet activity, we tested the lytic potential of splenocytes obtained after administration of the IL-2 minipellet in a 51Cr release assay. Cytotoxicity against YAC-1 cells and colon 26 cells was significantly augmented on Day 2 after minipellet administration. These results demonstrated that local administration of the IL-2 minipellet into the hepatic circulation was extremely effective against metastatic liver cancer.
Asunto(s)
Adenocarcinoma/terapia , Neoplasias del Colon/terapia , Inmunoterapia , Interleucina-2/administración & dosificación , Neoplasias Hepáticas/secundario , Animales , Preparaciones de Acción Retardada , Interleucina-2/sangre , Interleucina-2/farmacología , Interleucina-2/uso terapéutico , Circulación Hepática/fisiología , Neoplasias Hepáticas/terapia , Masculino , Ratones , Ratones Endogámicos BALB C , Bazo/citología , Bazo/fisiologíaRESUMEN
We investigated alterations in protein kinase C (PKC) activity of PANC-1 cells following treatment with tumour necrosis factor (TNF)-alpha or TNF-beta by an in vitro autoradiographic method. Binding studies performed on whole cells using [3H]phorbol-12,13-dibutyrate (PDBu) as a ligand revealed strong activation of PKC by TNFs within 30 min. The effect was similar to that seen after 30 min treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). After treatment for 24 h, TNF-beta caused a marked down-regulation of PKC similar to that seen after 24 h treatment with TPA; significant activation persisted, however, in the cells treated for 24 h with TNF-alpha. Our data suggest that PKC activation may play a more important role in the TNF-alpha signal transduction pathway than in that of TNF-beta.
Asunto(s)
Linfotoxina-alfa/farmacología , Neoplasias Pancreáticas/metabolismo , Proteína Quinasa C/biosíntesis , Transducción de Señal , Factor de Necrosis Tumoral alfa/farmacología , Autorradiografía , Inducción Enzimática , Humanos , Técnicas In Vitro , Células Tumorales CultivadasRESUMEN
Interleukin-18 (IL-18) is a new inflammatory cytokine sharing biological functions with IL-12. The human IL-18 receptor (IL-18R) was recently identified and was found to be expressed on normal peripheral blood lymphocytes. To further characterize IL-18R, we analyzed IL-18R expression using a series of human hematopoietic cell lines selected from various cell lineages. We found the IL-18R expression on cells of T and B lineages as expected from analysis on normal cells. The IL-18R expression, however, was found not to be restricted to any specific maturation stages of T and B cells. In addition, we detected IL-18R expression in myeloid, monocytoid, erythroid and megakaryocytic cell lines, indicating that normal counterparts of these cell lineages could express IL-18R and participate in in vivo reactions caused by IL-18. Biochemical studies showed that IL-18R proteins exist as heterogeneous molecules ranging from 60 to 110 kDa. Deglycosylation experiments indicated that the heterogeneity could not be explained only by a difference in glycosylation. We also found that tumor necrosis factor-alpha (TNF-alpha) modulated the IL-18R expression, which implies an important in vivo effect of TNF-alpha on IL-18-induced reaction. Analyzing the responsiveness of IL-18R, we found that only KG-1 responded to IL-18 stimulation. This suggests that certain inhibitory mechanisms of IL-18 responsive genes are involved in the all IL-18R-positive cell lines except KG-1.
Asunto(s)
Células de la Médula Ósea/metabolismo , Receptores de Interleucina/genética , Linfocitos B/inmunología , Western Blotting , Células de la Médula Ósea/inmunología , Línea Celular Transformada , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Glicosilación , Humanos , Interleucina-12/farmacología , Interleucina-18/metabolismo , Subunidad alfa del Receptor de Interleucina-18 , Receptores de Interleucina/metabolismo , Receptores de Interleucina-18 , Linfocitos T/inmunología , Factor de Necrosis Tumoral alfa/farmacología , Regulación hacia ArribaRESUMEN
A human acute lymphoblastic leukemia (ALL) cell line, BALM-16, was established from the peripheral blood specimen of a patient with B cell ALL L3 type (ALL-L3) in relapse. As with the original leukemia cells, the established line was negative for both cell surface and cytoplasmic immunoglobulin (Ig) chains. Absence of Ig expression was confirmed by Western blotting. Southern blot analysis demonstrated homozygous deletion of the C kappa gene, germ line configuration of the C lambda and rearrangement of IgJH genes. Cytogenetic analysis of both leukemic bone marrow and BALM-16 cells showed the t(8;22)(q24;q11) abnormality which is specifically associated with ALL-L3 and Burkitt lymphoma. The patient's serum showed hypercalcemia, prompting further investigation of the established cell lines which showed parathyroid hormone-related peptide (PTHrP) mRNA detected by reverse-transcriptase polymerase chain reaction. However, PTHrP production was not detected in the culture supernatant. The established cell line, BALM-16, could provide a useful material for analyzing the lack of Ig expression and of clarifying the pathogenesis of this type of B cell malignancy.
Asunto(s)
Hipercalcemia/inmunología , Inmunoglobulinas/análisis , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Adulto , Antígenos CD/análisis , Southern Blotting , Aberraciones Cromosómicas , Genes de Inmunoglobulinas , Humanos , Masculino , Proteína Relacionada con la Hormona Paratiroidea , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proteínas/análisis , Células Tumorales CultivadasRESUMEN
We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is associated with a minute chromosomal insertion, ins(11;9)(q23;p22p23). MOLM-13 and MOLM-14 are the first cell lines with, and represent the third reported case of, MLL gene rearrangement arising via chromosomal insertion. Both cell lines carry trisomy 8 which was also present during the MDS phase, as well as the most frequent trisomies associated with t(9;11), ie, +6, +13, +19 variously present in different subclones. Despite having these features in common, differences in antigen expression were noted between the two cell lines: that of MOLM-13 being CD34+, CD13-, CD14-, CD15+, CD33+; whereas MOLM-14 was CD4+, CD13+, CD14+, CD15+, CD33+. Differentiation to macrophage-like morphology could be induced in both cell lines after stimulation with INF-gamma alone, or in combination with TNF-alpha, which treatment also induced or upregulated, expression of certain myelomonocyte-associated antigens, including CD13, CD14, CD15, CD64, CD65 and CD87. Together, these data confirm that both cell lines are likely to be novel in vitro models for studying monocytic differentiation and leukemogenesis.
Asunto(s)
Aberraciones Cromosómicas/genética , ADN de Neoplasias/genética , Proteínas de Unión al ADN/genética , Leucemia Monocítica Aguda/genética , Proteínas Nucleares/genética , Proto-Oncogenes , Factores de Transcripción , Células Tumorales Cultivadas , Adulto , Antígenos CD/metabolismo , Bandeo Cromosómico , Trastornos de los Cromosomas , Cromosomas Humanos Par 11 , Cromosomas Humanos Par 9 , Citocinas/farmacología , Regulación Neoplásica de la Expresión Génica , N-Metiltransferasa de Histona-Lisina , Humanos , Inmunofenotipificación , Hibridación Fluorescente in Situ , Cariotipificación , Masculino , Proteína de la Leucemia Mieloide-Linfoide , Fenotipo , ARN Mensajero/genéticaRESUMEN
GlyCAM-1 (glycosylation-dependent cell adhesion molecule-1) is one of the sialomucin-like ligands for L-selectin, which is a member of the selectin family and mediates initial adhesion of leukocytes to specialized high endothelial venules in lymph nodes and venules at sites of inflammation. GlyCAM-1, lacking a transmembrane domain, is supposed to be secreted into the blood. To understand the functional role of secreted GlyCAM-1, we performed sandwich enzyme-linked immunosorbent assay to measure GlyCAM-1 plasma levels after inflammatory stimulus. BALB/c mice were injected with complete Freund's adjuvant (CFA) in the hind footpads; serum levels of GlyCAM-1 and L-selectin bound to GlyCAM-1 and several inflammatory cytokines, including interleukin-6 (IL-6), were measured at various intervals. IL-6 showed a significant increase 3 h after CFA stimulation. GlyCAM-1 was increased at 3 h, reached peak levels at 12 h, and gradually decreased thereafter. Levels of L-selectin bound to the plasma GlyCAM-1 changed over a similar time course, reached peak at 12 h after, and then began to decrease. The binding of L-selectin to plasma GlyCAM-1 was completely eliminated with the presence of ethyleneglycol-bis(beta-aminoethylether)-N,N'-tetraacetic acid, showing the calcium dependency of this binding. These findings show that GlyCAM-1 release is enhanced by inflammatory stimulation and also suggest that released plasma GlyCAM-1 may trap, at least in part, soluble L-selectin shed from stimulated leukocytes to neutralize each other.
Asunto(s)
Inflamación/sangre , Selectina L/metabolismo , Mucinas/sangre , Animales , Calcio/metabolismo , Quelantes/farmacología , Citocinas/sangre , Ácido Egtácico/farmacología , Adyuvante de Freund/toxicidad , Inflamación/inducido químicamente , Interleucina-6/sangre , Ligandos , Masculino , Ratones , Ratones Endogámicos BALB C , Unión Proteica/efectos de los fármacosRESUMEN
Intercellular adhesion molecule-1 (ICAM-1, CD54) is a membrane glycoprotein and a member of the immunoglobulin superfamily. It plays a central role in cell to cell-mediated immune responses and is a ligand for leukocyte function-associated antigen-1 (LFA-1). We report here that a newly discovered cytokine, interferon-gamma-inducing factor (IGIF) [H. Okamura et al. (1995) Nature 378, 88] recently proposed to be designated as IL-18, selectively up-regulates ICAM-1 expression in KG-1 cells, a human myelomonocytic cell line, in which IL-18 also enhances interferon-gamma production. IL-18 induced heterotypic aggregation between KG-1 and Peer T cells, which was blocked by anti-ICAM-1 and/or LFA-1 antibodies. Anti-interferon-gamma antibody did not block the IL-18-induced up-regulation of ICAM-1 on KG-1 cells. These results thus show that IGIF/IL-18, enhances ICAM-1 expression in KG-1 cells in an interferon-gamma-independent pathway, up-regulates ICAM-1 functions, and that IL-18 might play a potential role in immunoregulation by mediating immune cell infiltration into the tissues.
Asunto(s)
Citocinas/farmacología , Regulación de la Expresión Génica/fisiología , Molécula 1 de Adhesión Intercelular/genética , Inductores de Interferón/farmacología , Interleucina-18/farmacología , Línea Celular , Citocinas/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Células HL-60 , Humanos , Receptores de Hialuranos/genética , Integrina alfa4beta1 , Integrinas/genética , Molécula 1 de Adhesión Intercelular/biosíntesis , Interferón gamma/biosíntesis , Interferón gamma/genética , Interferón gamma/farmacología , Interleucina-18/fisiología , Cinética , Selectina L/genética , Leucemia Mielomonocítica Aguda , Antígeno-1 Asociado a Función de Linfocito/genética , Receptores Mensajeros de Linfocitos/genética , Proteínas Recombinantes/farmacología , Linfocitos T , Células Tumorales Cultivadas , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
Perforin is a protein present in the cytoplasmic granules of killer cells and is considered to be an important effector molecule. We assessed the perforin appearance via flow cytometry in human peripheral blood mononuclear cells stimulated in vitro for 3 days by recombinant interleukin-2 (rIL-2) or OK-432, a biological response modifier. The relationship between the lymphocyte subsets and perforin was investigated via two-color assay. CD4-positive cells had almost no perforin, and most of the CD16-positive cells did. Regarding the relationship with CD8, some of the bright positive cells (which were likely T cells) and most of the dull positive cells (likely NK cells) had perforin. Mean fluorescence was greatest in perforin-positive cells incubated with rIL-2, less in cells incubated with OK-432, and minimal in cells incubated in a medium without additives. Immunohistochemical staining with antiperforin antibody revealed that blast-transformed and enlarge cells were stained positively and that the intensity of staining of each cell alone was enhanced in cells incubated with OK-432 or rIL-2. If the fluorescence intensity of perforin-positive cells correlates with the amount of perforin in those cells, then the appearance of perforin was enhanced with OK-432, more enhanced with rIL-2, and consistent for cytotoxicity against K562 and Daudi cells. IL-2 was induced by OK-432, suggesting that the indirect effect of this IL-2 may play a role in OK-432-perforin induction. The results suggest that perforin may be an effector molecule in killer cells induced by rIL-2 or OK-432.
Asunto(s)
Leucocitos Mononucleares/metabolismo , Glicoproteínas de Membrana , Proteínas de la Membrana/biosíntesis , Citotoxicidad Inmunológica , Citometría de Flujo , Humanos , Técnicas In Vitro , Interleucina-2/farmacología , Leucocitos Mononucleares/inmunología , Perforina , Picibanil/farmacología , Proteínas Citotóxicas Formadoras de Poros , Células Tumorales Cultivadas/inmunologíaRESUMEN
A polysaccharide preparation isolated from Coriolus versicolor (Fr.) Quél. of Basidiomycetes (PSK) predominantly consists of glucan and approximately 25% tightly bound protein. PSK was effective against various allogeneic and syngeneic animal tumors and has been given orally to cancer patients. Various suppressed or enhanced immune responses of tumor-bearing animals were restored to normal levels by the administration of PSK in the tumor models tested. The killer T cell activity was augmented in tumor-bearing mice by intraperitoneal or oral administration of PSK, and there was correlation between the PSK associated antitumor effect and the killer T cell activity. It was found that PSK competed with immunosuppressive substances isolated from tumor-bearing mice and that the intestinal immune system appeared to be modulated by oral administration of PSK. After oral administration of 14C- or 35S-labeled PSK to normal rats, it was found that small or large molecular substances appeared in the serum depending on the time elapsed after administration, an indication that large molecular size products were from the digestive tract.
Asunto(s)
Antibióticos Antineoplásicos/uso terapéutico , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Proteoglicanos/uso terapéutico , Aminoácidos/análisis , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carbohidratos/análisis , Ensayos Clínicos como Asunto , Terapia Combinada , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Células Asesinas Naturales/inmunología , Macrófagos/inmunología , Ratones , Ratones Endogámicos , Plasmacitoma/tratamiento farmacológico , Plasmacitoma/radioterapia , Proteoglicanos/administración & dosificación , Proteoglicanos/toxicidad , Linfocitos T Reguladores/inmunologíaRESUMEN
Constitutive production of hydroxyl radicals from four established cancer cell lines was detected as spin adducts of 5,5-dimethyl-l-pyroline-N-oxide (DMPO), using an electron spin resonance spectrometer. The generated hydroxyl radicals was decreased in three out of four cancer cell lines when incubated in vitro for 3 h with TNF-alpha No direct scavenging effect of TNF-alpha on hydroxyl radicals or superoxide anions was observed in the in vitro radical generation system. The modulation of intracellular reactive oxygen species of these cancer cells by adding menadione or CuDIPS to the culture medium changed the antiproliferative effect of TNF-alpha on the cells. The ultrastructural localization of the radical-generating sites in cancer cells was visualized using the diaminobenzidine/horseradish peroxide histochemical system at the electron microscopic level. The hydrogen peroxide-dependent formation of electron-dense materials localized at the mitochondrial membranes was decreased after the treatment of the cancer cells with TNF-alpha. These data indicate that the reduction of radical generation in cancer cells by TNF-alpha may be an early mechanism that contributes to the antiproliferative effect of this cytokine on some cancer cells.
Asunto(s)
Depuradores de Radicales Libres/farmacología , Factor de Necrosis Tumoral alfa/farmacología , División Celular/efectos de los fármacos , Óxidos N-Cíclicos , Espectroscopía de Resonancia por Spin del Electrón , Radicales Libres/metabolismo , Humanos , Radical Hidroxilo/metabolismo , Microscopía Electrónica , Especies Reactivas de Oxígeno/metabolismo , Salicilatos/farmacología , Marcadores de Spin , Superóxidos/metabolismo , Células Tumorales Cultivadas , Vitamina K/farmacologíaRESUMEN
An antagonistic activity against vascular endothelial growth factor (VEGF) was identified in the culture supernatants of certain human hematopoietic cell lines and the antagonistic protein was purified from NALM-16 (B cell) culture supernatant. Amino acid sequencing of the N-terminus and Western blot analysis confirmed that the antagonist was identical to a soluble truncated form of Flt-1 (sFlt-1). Seventeen of 52 leukemia and lymphoma cell lines investigated expressed sFlt-1 mRNA, and 16 of the sFlt-1 expressing cells also expressed VEGF and membrane-bound Flt-1 (mFlt-1). This report is the first showing that sFlt-1 can be produced by malignant hematopoietic cells, suggesting that the production of VEGF antagonist by hematopoietic cells may play some role in the regulation of VEGF activity in normal and malignant hematopoietic cell proliferation.
Asunto(s)
Linfocitos B/química , Factores de Crecimiento Endotelial/antagonistas & inhibidores , Linfocinas/antagonistas & inhibidores , Proteínas Proto-Oncogénicas/aislamiento & purificación , Proteínas Tirosina Quinasas Receptoras/aislamiento & purificación , Secuencia de Aminoácidos , Western Blotting , Línea Celular , Medios de Cultivo Condicionados , Hematopoyesis , Humanos , Datos de Secuencia Molecular , Unión Proteica , Proteínas Proto-Oncogénicas/farmacología , ARN Mensajero/metabolismo , Proteínas Tirosina Quinasas Receptoras/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Homología de Secuencia de Aminoácido , Solubilidad , Factor A de Crecimiento Endotelial Vascular , Receptor 1 de Factores de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial VascularRESUMEN
Adjuvant immunochemotherapy using the antitumour polysaccharide sizofiran (SPG), an extract from the culture broth of Schizophyllum commune Fries, was prescribed randomly for 386 Japanese patients with resectable gastric cancer. Although the overall survival probability for 5 years did not differ between the SPG and control groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the sizofiran-administered patients was better than in the controls. In the multivariate analysis, four of six prognostic factors correlated with the prognosis of the 264 patients who underwent curative surgery, that is, nodal involvement (chi 2 = 21.426, P = less than 0.0001), age distribution (chi 2 = 9.262, P = 0.010), sizofiran administration (chi 2 = 6.507, P = 0.011), and primary tumour size (chi 2 = 9.345, P = 0.025). Thus, patients with a curatively resected gastric cancer had a better prognosis when sizofiran was prescribed in combination with antitumour drugs.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Sizofirano/uso terapéutico , Neoplasias Gástricas/tratamiento farmacológico , Adyuvantes Inmunológicos/efectos adversos , Anciano , Femenino , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Sizofirano/efectos adversos , Neoplasias Gástricas/mortalidadRESUMEN
Between 1985 and 1988, the effect of using ftorafur (FT) or PSK (an immunotherapy agent) in combination with the conventional postoperative adjuvant therapy using mitomycin (MMC) plus tamoxifen (TAM) was assessed in stage II, oestrogen receptor-positive (ER+) breast cancer patients. Furthermore, in ER- breast cancer stage II patients, the effects of postoperative adjuvant therapy using MMC plus FT were compared with the effects of postoperative adjuvant therapy using MMC plus PSK. Patients had primary stage II breast cancer and had undergone total mastectomy plus axillary dissection or more radical surgery. On the day of surgery, MMC (13 mg/m2) was administered intravenously. Then, ER+ patients received one of three regimens of drug therapy, starting 2 weeks after surgery: regimen A (daily oral treatment with 30 mg of TAM), regimen B (daily oral treatment with 30 mg of TAM and 600 mg of FT) or regimen C (daily oral treatment with 30 mg of TAM and 3 g of PSK) [corrected]. ER- patients received either regimen D (daily oral treatment with 600 mg of FT) or regimen E (daily oral treatment with 3 g of PSK), starting 2 weeks after surgery. Of the 540 ER+ patients registered, 525 were evaluated. The 5-year overall survival rate for ER+ patients was higher for patients who received regimen B (94.2%) than for those who received regimen A (86.9%) or regimen C (89.9%) (P = 0.063). The 5-year relapse-free survival rate was higher for regimen B (88.9%) than for regimen A (78.6%) and regimen C (77.2%) (P = 0.010). Stratified analysis revealed better results with the FT-combined therapy in patients positive for lymph node metastasis and premenopausal patients. These results indicate the effectiveness of using FT in combination with TAM. Of the 376 ER- patients registered, 364 were evaluated. The 5-year overall and relapse-free survival rate for ER- patients did not differ significantly between patients who received regimen D and those who received regimen E.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/terapia , Factores Inmunológicos/uso terapéutico , Proteoglicanos/uso terapéutico , Adulto , Anciano , Antimetabolitos Antineoplásicos/administración & dosificación , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Supervivencia sin Enfermedad , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Mitomicina/administración & dosificación , Metástasis de la Neoplasia , Tasa de Supervivencia , Tamoxifeno/administración & dosificación , Tegafur/administración & dosificaciónRESUMEN
Interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) is a novel cytokine which plays an important role in Th1 responses. Here we describe a simple, sensitive bioassay for human IL-18 using the human myelomonocytic cell line, KG-1, which produces IFN-gamma in response to human IL-18. IFN-gamma production induced by human IL-18 was completely blocked by an antibody against human IL-18. Human IL-18 could be measured in a concentration range from approximately 100 to 10,000 pg/ml, and intra- and inter-assay coefficient variations were both below 15%. It was possible to measure human IL-18 in human serum, cell lysate or culture supernatant by this bioassay. Thus, the human IL-18 bioassay can be expected to be useful in the investigation of the relationship between human IL-18 and various diseases or in analyzing the mechanisms of human IL-18 secretion from IL-18 producing cells.
Asunto(s)
Bioensayo , Citocinas/biosíntesis , Inductores de Interferón/análisis , Interferón gamma/biosíntesis , Animales , Reacciones Cruzadas , Citocinas/farmacología , Humanos , Inductores de Interferón/farmacología , Interleucina-18 , Ratones , Sensibilidad y Especificidad , Células Tumorales CultivadasRESUMEN
Conventional enzyme-linked immunosorbent assays (ELISA) are sufficient to measure normal and elevated serum interleukin (IL)-18 concentrations, but have limited sensitivity when measuring low concentrations of IL-18 such as in patients with the acquired immunodeficiency syndrome. We have developed a highly sensitive method for detecting human (h) IL-18 using an immuno-polymerase chain reaction (PCR). A mouse monoclonal anti-hIL-18 antibody and rabbit polyclonal anti-hIL-18 antibody was used for an indirect sandwich ELISA with a detection limit of 40 ng/l and a very low background. For immuno-PCR, biotinylated DNA was produced from the plasmid Bluescript by PCR amplification with biotinylated M13-20 primer and nonbiotinylated M13 reverse primer. Immuno-PCR for hIL-18 was performed for 40 cycles using 1 ng/l of biotinylated DNA. This immuno-PCR has a detection limit of 2.5 pg/l, 1.6x10(4) times lower than that of the ELISA. In addition, our system avoids sampling error caused by heat transfer from the ELISA plate to the PCR tube because all procedures from immobilization of the antibody to PCR amplification can be performed in the same tube. This immuno-PCR for hIL-18 is the most sensitive method for detecting hIL-18 reported to date.
Asunto(s)
Interleucina-18/análisis , Reacción en Cadena de la Polimerasa/métodos , Animales , Secuencia de Bases , Medios de Cultivo , Ensayo de Inmunoadsorción Enzimática/métodos , Humanos , Interleucina-18/genética , Interleucina-18/inmunología , Macrófagos/citología , Macrófagos/inmunología , Ratones , Datos de Secuencia Molecular , Conejos , Sensibilidad y EspecificidadRESUMEN
Interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) is a novel cytokine, which is a potent inducer of IFN-gamma production and plays an important role in Th1 responses. In order to develop a specific ELISA for the measurement of human IL-18, we established 13 anti-human IL-18 monoclonal antibodies and characterized them. 7 murine anti-human IL-18 mAbs and 6 rat anti-human IL-18 mAbs were obtained by fusion of splenocytes from mice or rats immunized with human IL-18, with SP2/0 myeloma cells. These antibodies were classified into 4 groups according to competitive binding ELISAs to the human IL-18 molecule. 1 murine mAb and all 6 rat mAbs neutralized IFN-gamma production induced by IL-18. A specific human IL-18 ELISA was developed using two neutralizing mAbs (#125-2H and #159-12B). This ELISA detects human IL-18 with a minimum detection limit of 10 pg/ml, but does not react with heat-denatured human IL-18. The ELISA does not show any cross-reactivity with other cytokines. Using this assay, human IL-18 was measurable in the plasma of leukemia patients. This ELISA would become a powerful tool for investigating the relationship between IL-18 and various diseases or analyzing the control mechanisms of IL-18 production from IL-18 producing cells.
Asunto(s)
Anticuerpos Monoclonales/química , Citocinas/sangre , Citocinas/inmunología , Interferón gamma/biosíntesis , Adulto , Animales , Línea Celular , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Interleucina-18 , Leucemia/sangre , Leucemia/inmunología , Ratones , Ratones Endogámicos BALB C , Conejos , Ratas , Ratas Sprague-DawleyRESUMEN
It has been shown that the nutritional state of the donor may affect the outcome of liver transplantation. However, many donors staying in the intensive care unit for a long period are in a reduced nutritional state. In this study, we investigated the effects of various methods of nutritional repletion on the outcome of liver transplantation in pigs. Donor pigs were divided into three groups according to the nutritional pretreatment given for 7 days before harvesting: group I were fasted and received intravenous administration of saline; group II were fed orally; group III were fasted, but given 20% glucose intravenously. Donor livers were stored for 4 hr in cold Euro-Collins' solution and transplanted. The serum AST level 24 hr after reperfusion remained at a lower level in group III compared with those in groups I and II. Bile production of the liver after transplantation was also well recovered in group III. The glycogen content of the liver at harvesting, which was completely consumed in group 1, was well preserved in groups II and III. These storages in both groups were rapidly consumed 1 hr after reperfusion. On the other hand, ATP content of the liver in groups I, II, and III, which were at a similar level at harvesting, were markedly decreased 4 hr after cold preservation and, 1 hr after reperfusion, recovered to 26%, 48%, and 73% of that before preservation, respectively. The mean survival time in group III was 37.2 days, significantly longer than 5.8 +/- 0.7 and 9.8 +/- 2.0 days in groups I and II, respectively (P < 0.01). These results show that the favorable outcome of liver transplantation depends on the glycogen storage in the donor liver, and also on ATP generation after reperfusion. Furthermore, it was suggested that ATP generation was affected by some unknown factor related to the method of nutritional repletion.
Asunto(s)
Trasplante de Hígado/métodos , Donantes de Tejidos , Adenosina Trifosfato/metabolismo , Animales , Aspartato Aminotransferasas/sangre , Bilis/metabolismo , Bilirrubina/sangre , Metabolismo Energético , Hígado/metabolismo , Glucógeno Hepático/metabolismo , Fenómenos Fisiológicos de la Nutrición , Análisis de Supervivencia , PorcinosRESUMEN
The interaction of interleukin 2 with specific cellular receptors plays an essential role in the allostimulated proliferation and differentiation of T cells. Recent chemical linking studies have demonstrated that the human high-affinity IL-2 receptor is a membrane complex composed of at least two distinct subunits, which are the p55 (alpha-chain) and p75 (beta-chain) subunits. The IL-2R beta chain is supposed to play a role in the signal transduction of IL-2, but the exact mechanism is still unknown. In this study, we investigated the effects of a newly established anti-IL-2R beta chain monoclonal antibody (MoAb, TU-27) on the induction of cytotoxic T lymphocytes (CTLs) using the cell-mediated lympholysis (CML) assay. TU-27 in combination with H-31, a MoAb directed against the IL-2R alpha chain, produced inhibition of cytotoxicity, while TU-27 alone could not inhibit cytotoxicity, while TU-27 alone could not inhibit cytotoxicity at any concentration. TU-27 plus H-31 prevented the expansion of CD4+ cells and CD8++ cells in mixed lymphocyte culture (MLC). Furthermore, we examined the serial changes in the expression of the IL-2R beta chain on peripheral blood lymphocytes from renal transplant recipients using two-color immunofluorescence flow cytometry, so as to investigate correlations between IL-2R beta chain expression and the occurrence of allograft rejection. Here, we report that the IL-2R beta chain is expressed on CD4-positive (CD4+) cells and strongly CD8-positive (CD8(+)+) cells in association with acute rejection, indicating that IL-2R beta chain expression appears to increase on alloreactive T cells.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Trasplante de Riñón/fisiología , Receptores de Interleucina-2/fisiología , Separación Celular/métodos , Citometría de Flujo , Humanos , Activación de Linfocitos/fisiología , Prueba de Cultivo Mixto de Linfocitos , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/fisiología , Receptores de Interleucina-2/inmunología , Subgrupos de Linfocitos T/inmunología , Linfocitos T Citotóxicos/fisiología , Linfocitos T Citotóxicos/ultraestructuraRESUMEN
We describe a patient transfused with 200 ml of donor fresh whole blood three times at 2-week intervals. Three weeks after the last transfusion, transplantation and splenectomy were done at the same time. Splenic cells from this DST pretreated patient were fused with murine myeloma cells (X63-Ag8, 653). With DST pretreatment, various clones were developed in vivo, and finally 69 human immunoglobulin-secreting clones were obtained. Modulation of the alloantigen-specific MLR by supernatants from 69 clones showed various degrees of suppression or augmentation. The hybridoma clone 7 and clone 2, which had been secreting IgG antibody for more than 6 months, showed some degree of suppression in the alloantigen-specific MLR (mean suppression = 63%, 46% respectively). According to the result of MLR, clone 7 antibody was directed against recipient lymphocytes and clone 2 antibody was against donor lymphocytes. Immunoprecipitation was carried out by clone 7-IgG and clone 2-IgG. Clone 7-IgG specifically precipitated 1 molecule from the recipient lymphocyte with a molecular weight of 120 KD, similar to the molecular weight range reported for T cell receptors. Clone 2-IgG precipitated a 20 KD molecule from the donor lymphocyte. The data suggest that DST induces antibodies directed against the blood donor alloantigen-specific receptors on the recipient's T lymphocytes--and, at the same time, induces antibodies against donor lymphocyte antigens. These antibodies may be essential to prolongation of kidney allograft survival following DST.